Gan & Lee's GZR18 Receives FDA IND Clearance for Phase 2 Obesity Trial
核心洞察
Gan & Lee Pharmaceuticals (搜索)' GZR18 injection, a bi-weekly GLP-1 receptor (搜索) agonist, has received FDA clearance for a Phase 2 trial.
The trial will compare GZR18 head-to-head with Tirzepatide for chronic weight management in obese or overweight patients.
GZR18 has shown comparable or better weight loss effects than weekly GLP-1 formulations in early clinical data.
Gan & Lee Pharmaceuticals (搜索) announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for GZR18 Injection. This clearance allows Gan & Lee to proceed with a Phase 2 clinical trial in the United States, directly comparing GZR18 to Tirzepatide for chronic weight management in obese or overweight patients, with or without type 2 diabetes (搜索) (T2DM). The trial is registered under NCT06737042.
GZR18 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (RA). As a bi-weekly GLP-1 mono-agonist formulation, GZR18 represents a novel approach to obesity (搜索) treatment. Current clinical data suggests that GZR18 can achieve weight loss effects comparable to, or even better than, multi-target once-weekly GLP-1 formulations.
Obesity Crisis and the Role of GLP-1 RAs
The World Obesity (搜索) Federation (WOF) Global Obesity Report (2024) indicates that approximately 2.2 billion adults worldwide were overweight (BMI ≥ 25kg/m2) in 2020, representing about 42% of the adult population. Projections estimate this number will rise to 3.3 billion by 2035. Obesity is associated with numerous complications, including diabetes, cardiovascular diseases (搜索), and mental health disorders, placing a substantial burden on healthcare systems.
GLP-1 receptor (搜索) agonists like GZR18 offer a therapeutic strategy by delaying gastric emptying and enhancing satiety through activation of GLP-1 receptors in the gastrointestinal tract and hypothalamus. This mechanism helps to suppress appetite and reduce body weight.
Clinical Development of GZR18
GZR18 is under development for both type 2 diabetes (搜索) and chronic weight management. Clinical data has demonstrated that administering GZR18 once a week or every two weeks can effectively lower blood sugar levels and promote weight loss. A Phase Ib/IIa trial showed that GZR18 induced an 18.6% weight reduction in subjects with obesity (搜索).
The bi-weekly administration schedule of GZR18 aims to provide more flexible treatment options for patients, potentially improving long-term weight management efficacy and adherence to therapy.
Gan & Lee Pharmaceuticals (搜索), known for developing the first Chinese domestic insulin analog, is expanding its focus to include treatments for metabolic and cardiovascular diseases (搜索).